Griffin JD - Search Results

1

Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells.

Sattler M, Pride YB, Quinnan LR, Verma S, Malouf NA, Husson H, Salgia R, Lipkowitz S, Griffin JD. Sattler M, et al. Among authors: griffin jd. Oncogene. 2002 Feb 21;21(9):1423-33. doi: 10.1038/sj.onc.1205202. Oncogene. 2002. PMID: 11857085

2

Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease.

Scheijen B, Griffin JD. Scheijen B, et al. Among authors: griffin jd. Oncogene. 2002 May 13;21(21):3314-33. doi: 10.1038/sj.onc.1205317. Oncogene. 2002. PMID: 12032772 Review.

3

Critical role for Gab2 in transformation by BCR/ABL.

Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K, Gesbert F, Iwasaki H, Li S, Van Etten RA, Gu H, Griffin JD, Neel BG. Sattler M, et al. Among authors: griffin jd. Cancer Cell. 2002 Jun;1(5):479-92. doi: 10.1016/s1535-6108(02)00074-0. Cancer Cell. 2002. PMID: 12124177 Free article.

4

Molecular mechanisms of transformation by the BCR-ABL oncogene.

Sattler M, Griffin JD. Sattler M, et al. Among authors: griffin jd. Semin Hematol. 2003 Apr;40(2 Suppl 2):4-10. doi: 10.1053/shem.2003.50034. Semin Hematol. 2003. PMID: 12783368 Review.

5

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.

Sattler M, Scheijen B, Weisberg E, Griffin JD. Sattler M, et al. Among authors: griffin jd. Adv Exp Med Biol. 2003;532:121-40. doi: 10.1007/978-1-4615-0081-0_11. Adv Exp Med Biol. 2003. PMID: 12908554 Review.

6

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R. Ma PC, et al. Among authors: griffin jd. Cancer Res. 2003 Oct 1;63(19):6272-81. Cancer Res. 2003. PMID: 14559814

7

FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins.

Scheijen B, Ngo HT, Kang H, Griffin JD. Scheijen B, et al. Among authors: griffin jd. Oncogene. 2004 Apr 22;23(19):3338-49. doi: 10.1038/sj.onc.1207456. Oncogene. 2004. PMID: 14981546

8

Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.

Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D, Salgia R, Podar K, Griffin JD, Sattler M. Kim JH, et al. Among authors: griffin jd. Blood. 2005 Feb 15;105(4):1717-23. doi: 10.1182/blood-2004-03-0849. Epub 2004 Oct 14. Blood. 2005. PMID: 15486067 Free article.

9

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD. Weisberg E, et al. Among authors: griffin jd. Cancer Cell. 2005 Feb;7(2):129-41. doi: 10.1016/j.ccr.2005.01.007. Cancer Cell. 2005. PMID: 15710326 Free article.

10

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.

Chen J, Lee BH, Williams IR, Kutok JL, Mitsiades CS, Duclos N, Cohen S, Adelsperger J, Okabe R, Coburn A, Moore S, Huntly BJ, Fabbro D, Anderson KC, Griffin JD, Gilliland DG. Chen J, et al. Among authors: griffin jd. Oncogene. 2005 Dec 15;24(56):8259-67. doi: 10.1038/sj.onc.1208989. Oncogene. 2005. PMID: 16091734

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

541 results

Search Page